Literature DB >> 11257176

Interferon-alpha inhibits hepatitis C virus subgenomic RNA replication by an MxA-independent pathway.

Michael Frese1, Thomas Pietschmann2, Darius Moradpour3, Otto Haller1, Ralf Bartenschlager2.   

Abstract

Hepatitis C virus (HCV) persists in the majority of infected individuals and is a major cause of chronic hepatitis, liver cirrhosis and hepatocellular carcinoma. Chronic hepatitis C is currently treated with interferon (IFN)-alpha or with a combination of IFN-alpha and ribavirin. The availability of an HCV replicon system (Lohmann et al., SCIENCE: 285, 110-113, 1999) allowed the investigation of the effects of IFN on genuine HCV replication in cultured cells. It is shown here that IFN-alpha inhibits subgenomic HCV RNA replication in HuH-7 human hepatoma cells. Immunofluorescence, Western blot and Northern blot analysis revealed that levels of both HCV protein and replicon RNA were reduced after treatment with IFN-alpha in a dose-dependent manner. In further experiments, it was investigated whether MxA plays a role in the inhibition of HCV. The human MxA protein is an IFN-induced GTPase that has antiviral activity against various RNA viruses. However, HCV RNA replication was not affected in transfected HuH-7 cells that transiently overexpressed MxA. Moreover, a dominant-negative mutant of MxA did not interfere with the antiviral activity of IFN-alpha against HCV RNA replication. Taken together, these results demonstrate that IFN-alpha inhibits HCV replicons via an MxA-independent pathway.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11257176     DOI: 10.1099/0022-1317-82-4-723

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  54 in total

1.  Synergistic in vitro interactions between alpha interferon and ribavirin against bovine viral diarrhea virus and yellow fever virus as surrogate models of hepatitis C virus replication.

Authors:  Victor E Buckwold; Jiayi Wei; Michelle Wenzel-Mathers; Julie Russell
Journal:  Antimicrob Agents Chemother       Date:  2003-07       Impact factor: 5.191

2.  Mutations around interferon sensitivity-determining region: a pilot resistance report of hepatitis C virus 1b in a Hong Kong population.

Authors:  Xiao-Ming Zhou; Paul Ks Chan; John S Tam
Journal:  World J Gastroenterol       Date:  2011-12-28       Impact factor: 5.742

3.  Therapeutic implications of hepatitis C virus resistance to antiviral drugs.

Authors:  Jean-Michel Pawlotsky
Journal:  Therap Adv Gastroenterol       Date:  2009-07       Impact factor: 4.409

4.  Impact of host responses on control of hepatitis C virus infection in Chinese blood donors.

Authors:  Tingting Li; Zixuan Chen; Jinfeng Zeng; Jingang Zhang; Wenjing Wang; Ling Zhang; Xin Zheng; Lifang Shuai; Paul Klenerman; Jean-Pierre Allain; Chengyao Li
Journal:  Biochem Biophys Res Commun       Date:  2011-10-29       Impact factor: 3.575

Review 5.  Stealth and cunning: hepatitis B and hepatitis C viruses.

Authors:  Stefan F Wieland; Francis V Chisari
Journal:  J Virol       Date:  2005-08       Impact factor: 5.103

6.  Clearance of chronic HCV infection during acute delta hepatitis.

Authors:  K Deterding; S V Pothakamuri; V Schlaphoff; J Hadem; F Metzler; M J Bahr; M P Manns; M Cornberg; H Wedemeyer
Journal:  Infection       Date:  2007-12-14       Impact factor: 3.553

7.  Cytopathic and noncytopathic interferon responses in cells expressing hepatitis C virus subgenomic replicons.

Authors:  Ju-Tao Guo; Qing Zhu; Christoph Seeger
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

8.  Regulation of hepatitis C virus replication by interferon regulatory factor 1.

Authors:  Nobuhiko Kanazawa; Masayuki Kurosaki; Naoya Sakamoto; Nobuyuki Enomoto; Yasuhiro Itsui; Tsuyoshi Yamashiro; Yoko Tanabe; Shinya Maekawa; Mina Nakagawa; Cheng-Hsin Chen; Sei Kakinuma; Shigeru Oshima; Tetsuya Nakamura; Takanobu Kato; Takaji Wakita; Mamoru Watanabe
Journal:  J Virol       Date:  2004-09       Impact factor: 5.103

Review 9.  Interaction of hepatitis C virus with the type I interferon system.

Authors:  Friedemann Weber
Journal:  World J Gastroenterol       Date:  2007-09-28       Impact factor: 5.742

10.  Refractoriness of hepatitis C virus internal ribosome entry site to processing by Dicer in vivo.

Authors:  Dominique L Ouellet; Isabelle Plante; Vincent Boissonneault; Cherifa Ayari; Patrick Provost
Journal:  J Negat Results Biomed       Date:  2009-08-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.